Published in Nat Mater on May 03, 2009
Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Lett (2010) 2.35
Delivery of siRNA therapeutics: barriers and carriers. AAPS J (2010) 2.15
Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proc Natl Acad Sci U S A (2012) 1.91
Engineering nano- and microparticles to tune immunity. Adv Mater (2012) 1.75
Therapeutic cell engineering with surface-conjugated synthetic nanoparticles. Nat Med (2010) 1.71
Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus. Sci Transl Med (2012) 1.68
Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission. PLoS Pathog (2015) 1.61
Layer-by-layer nanoparticles for systemic codelivery of an anticancer drug and siRNA for potential triple-negative breast cancer treatment. ACS Nano (2013) 1.47
Therapeutic siRNA: principles, challenges, and strategies. Yale J Biol Med (2012) 1.35
A holistic approach to targeting disease with polymeric nanoparticles. Nat Rev Drug Discov (2015) 1.31
MicroRNAs in the ionizing radiation response and in radiotherapy. Curr Opin Genet Dev (2013) 1.30
Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates. Proc Natl Acad Sci U S A (2014) 1.30
Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug. Proc Natl Acad Sci U S A (2013) 1.30
Enhanced siRNA delivery into cells by exploiting the synergy between targeting ligands and cell-penetrating peptides. Biomaterials (2011) 1.24
In vivo distribution of surface-modified PLGA nanoparticles following intravaginal delivery. J Control Release (2011) 1.20
Advances in polymeric and inorganic vectors for nonviral nucleic acid delivery. Ther Deliv (2011) 1.17
Polymer nanoparticles mediated codelivery of antimiR-10b and antimiR-21 for achieving triple negative breast cancer therapy. ACS Nano (2015) 1.13
Differentially charged hollow core/shell lipid-polymer-lipid hybrid nanoparticles for small interfering RNA delivery. Angew Chem Int Ed Engl (2011) 1.13
Nanoparticles deliver triplex-forming PNAs for site-specific genomic recombination in CD34+ human hematopoietic progenitors. Mol Ther (2010) 1.13
Polymer--cisplatin conjugate nanoparticles for acid-responsive drug delivery. ACS Nano (2010) 1.12
A rapid pathway toward a superb gene delivery system: programming structural and functional diversity into a supramolecular nanoparticle library. ACS Nano (2010) 1.10
Synergistic silencing: combinations of lipid-like materials for efficacious siRNA delivery. Mol Ther (2011) 1.10
Polymeric nanoparticles for drug delivery to the central nervous system. Adv Drug Deliv Rev (2011) 1.09
Antiretroviral release from poly(DL-lactide-co-glycolide) nanoparticles in mice. J Antimicrob Chemother (2010) 1.07
Emerging nanotechnology approaches for HIV/AIDS treatment and prevention. Nanomedicine (Lond) (2010) 1.05
Synthetic poly(ester amine) and poly(amido amine) nanoparticles for efficient DNA and siRNA delivery to human endothelial cells. Int J Nanomedicine (2011) 1.01
Long-circulating siRNA nanoparticles for validating Prohibitin1-targeted non-small cell lung cancer treatment. Proc Natl Acad Sci U S A (2015) 1.01
A small library of DNA-encapsulated supramolecular nanoparticles for targeted gene delivery. Chem Commun (Camb) (2010) 1.00
In vivo sustained release of siRNA from solid lipid nanoparticles. ACS Nano (2011) 0.99
Getting into the brain: Potential of nanotechnology in the management of NeuroAIDS. Adv Drug Deliv Rev (2016) 0.98
Targeting of tumor-associated macrophages made possible by PEG-sheddable, mannose-modified nanoparticles. Mol Pharm (2013) 0.97
Nanoparticle delivery of antisense oligonucleotides and their application in the exon skipping strategy for Duchenne muscular dystrophy. Nucleic Acid Ther (2014) 0.97
Polymer nanoparticle-mediated delivery of microRNA inhibition and alternative splicing. Mol Pharm (2012) 0.96
Chimeric aptamers in cancer cell-targeted drug delivery. Crit Rev Biochem Mol Biol (2011) 0.96
Nanotherapy for Cancer: Targeting and Multifunctionality in the Future of Cancer Therapies. ACS Biomater Sci Eng (2015) 0.95
Vaginal delivery of paclitaxel via nanoparticles with non-mucoadhesive surfaces suppresses cervical tumor growth. Adv Healthc Mater (2013) 0.95
Polymer nanoparticles encapsulating siRNA for treatment of HSV-2 genital infection. J Control Release (2012) 0.95
siRNA applications in nanomedicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2010) 0.95
Supramolecular self-assembled nanoparticles mediate oral delivery of therapeutic TNF-α siRNA against systemic inflammation. Angew Chem Int Ed Engl (2013) 0.94
Sustained delivery of proangiogenic microRNA-132 by nanoparticle transfection improves endothelial cell transplantation. FASEB J (2013) 0.94
Vectoring siRNA therapeutics into the clinic. Nat Rev Clin Oncol (2010) 0.94
Acid-degradable cationic dextran particles for the delivery of siRNA therapeutics. Bioconjug Chem (2011) 0.92
Recent developments in nanoparticle-based siRNA delivery for cancer therapy. Biomed Res Int (2013) 0.92
pH-responsive nanoparticles releasing tenofovir intended for the prevention of HIV transmission. Eur J Pharm Biopharm (2011) 0.90
Nano-fibrous tissue engineering scaffolds capable of growth factor delivery. Pharm Res (2011) 0.90
Polymer nanoparticles for drug and small silencing RNA delivery to treat cancers of different phenotypes. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2013) 0.90
An MRI-visible non-viral vector for targeted Bcl-2 siRNA delivery to neuroblastoma. Int J Nanomedicine (2012) 0.88
siRNA knock-down of RANK signaling to control osteoclast-mediated bone resorption. Pharm Res (2010) 0.88
Device-based local delivery of siRNA against mammalian target of rapamycin (mTOR) in a murine subcutaneous implant model to inhibit fibrous encapsulation. J Control Release (2010) 0.88
Formulation of Anti-miR-21 and 4-Hydroxytamoxifen Co-loaded Biodegradable Polymer Nanoparticles and Their Antiproliferative Effect on Breast Cancer Cells. Mol Pharm (2015) 0.87
Systemic delivery of triplex-forming PNA and donor DNA by nanoparticles mediates site-specific genome editing of human hematopoietic cells in vivo. Gene Ther (2012) 0.87
Development and evaluation of a thermosensitive vaginal gel containing raltegravir+efavirenz loaded nanoparticles for HIV prophylaxis. Antiviral Res (2012) 0.87
Engineering tenofovir loaded chitosan nanoparticles to maximize microbicide mucoadhesion. Eur J Pharm Sci (2011) 0.87
Optimizing siRNA delivery to the genital mucosa. Discov Med (2011) 0.86
Ex vivo characterization of particle transport in mucus secretions coating freshly excised mucosal tissues. Mol Pharm (2013) 0.86
Selective local delivery of RANK siRNA to bone phagocytes using bone augmentation biomaterials. Biomaterials (2012) 0.85
Engineered phage-based therapeutic materials inhibit Chlamydia trachomatis intracellular infection. Biomaterials (2012) 0.85
PLGA-PLL-PEG-Tf-based targeted nanoparticles drug delivery system enhance antitumor efficacy via intrinsic apoptosis pathway. Int J Nanomedicine (2015) 0.84
Effects of glucocorticoid receptor small interfering RNA delivered using poly lactic-co-glycolic acid microparticles on proliferation and differentiation capabilities of human mesenchymal stromal cells. Tissue Eng Part A (2012) 0.84
Drug delivery: Old polymer learns new tracts. Nat Mater (2009) 0.84
Application of nanotechnologies for improved immune response against infectious diseases in the developing world. Adv Drug Deliv Rev (2009) 0.84
Well-defined degradable cationic polylactide as nanocarrier for the delivery of siRNA to silence angiogenesis in prostate cancer. Adv Healthc Mater (2012) 0.84
Surface-modified nanoparticles enhance transurothelial penetration and delivery of survivin siRNA in treating bladder cancer. Mol Cancer Ther (2013) 0.84
Nanoparticle penetration of human cervicovaginal mucus: the effect of polyvinyl alcohol. J Control Release (2014) 0.83
Multifunctional nanocapsules for simultaneous encapsulation of hydrophilic and hydrophobic compounds and on-demand release. ACS Nano (2012) 0.83
Broad-spectrum antiviral activity of RNA interference against four genotypes of Japanese encephalitis virus based on single microRNA polycistrons. PLoS One (2011) 0.83
Controlled release for local delivery of drugs: barriers and models. J Control Release (2014) 0.83
A review of nanotechnological approaches for the prophylaxis of HIV/AIDS. Biomaterials (2013) 0.83
Microbicides and HIV: A Review and an update. Indian J Sex Transm Dis (2012) 0.83
Nanoparticle-based drug delivery to the vagina: a review. J Control Release (2014) 0.83
Prevention of K-Ras- and Pten-mediated intravaginal tumors by treatment with camptothecin-loaded PLGA nanoparticles. Drug Deliv Transl Res (2011) 0.82
Polymer delivery systems for site-specific genome editing. J Control Release (2011) 0.82
Nanoparticle transport from mouse vagina to adjacent lymph nodes. PLoS One (2012) 0.82
Cell penetrating peptide-modified poly(lactic-co-glycolic acid) nanoparticles with enhanced cell internalization. Acta Biomater (2015) 0.82
Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis. PLoS One (2013) 0.81
Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer. Nanomedicine (2013) 0.81
Nanoparticle for delivery of antisense γPNA oligomers targeting CCR5. Artif DNA PNA XNA (2013) 0.80
Technologies for controlled, local delivery of siRNA. J Control Release (2015) 0.80
RNA therapeutics targeting osteoclast-mediated excessive bone resorption. Adv Drug Deliv Rev (2011) 0.80
Effect of small interfering RNA 3'-end overhangs on chemosensitivity to thymidylate synthase inhibitors. Silence (2011) 0.80
RNA interference for the treatment of papillomavirus disease. Open Virol J (2012) 0.80
A microparticle/hydrogel combination drug-delivery system for sustained release of retinoids. Invest Ophthalmol Vis Sci (2012) 0.80
Enhanced uptake and transport of PLGA-modified nanoparticles in cervical cancer. J Nanobiotechnology (2016) 0.79
Effect of pendant group on pDNA delivery by cationic-β-cyclodextrin:alkyl-PVA-PEG pendant polymer complexes. Biomacromolecules (2013) 0.79
Triggered rapid degradation of nanoparticles for gene delivery. J Drug Deliv (2012) 0.79
Non-viral nucleic acid containing nanoparticles as cancer therapeutics. Expert Opin Drug Deliv (2016) 0.79
Liposomes for HIV prophylaxis. Biomaterials (2011) 0.79
Regeneration of mammalian cochlear and vestibular hair cells through Hes1/Hes5 modulation with siRNA. Hear Res (2013) 0.79
Modified poly(lactic-co-glycolic acid) nanoparticles for enhanced cellular uptake and gene editing in the lung. Adv Healthc Mater (2014) 0.79
miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer. Cancer Res (2015) 0.79
siRNA-based topical microbicides targeting sexually transmitted infections. Curr Opin Mol Ther (2010) 0.79
Synergistic tumor suppression by combined inhibition of telomerase and CDKN1A. Proc Natl Acad Sci U S A (2014) 0.79
Single-stranded γPNAs for in vivo site-specific genome editing via Watson-Crick recognition. Curr Gene Ther (2014) 0.79
Novel intravaginal nanomedicine for the targeted delivery of saquinavir to CD4+ immune cells. Int J Nanomedicine (2013) 0.79
Polymeric Nanomedicines Based on Poly(lactide) and Poly(lactide-co-glycolide). Curr Opin Solid State Mater Sci (2012) 0.78
Nanoparticles as Drug Delivery Systems in Cancer Medicine: Emphasis on RNAi-Containing Nanoliposomes. Pharmaceuticals (Basel) (2013) 0.78
Bioengineered nanoparticles for siRNA delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2013) 0.78
Cervical mucus properties stratify risk for preterm birth. PLoS One (2013) 0.78
Targeting noncoding RNAs in disease. J Clin Invest (2017) 0.78
Biodegradation, biocompatibility, and drug delivery in poly(ω-pentadecalactone-co-p-dioxanone) copolyesters. Biomaterials (2011) 0.77
Regulated portals of entry into the cell. Nature (2003) 15.33
Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov (2009) 12.46
RNAi-mediated gene silencing in non-human primates. Nature (2006) 7.60
The promises and pitfalls of RNA-interference-based therapeutics. Nature (2009) 7.53
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A (2006) 6.90
Unlocking the potential of the human genome with RNA interference. Nature (2004) 6.70
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol (2005) 6.40
siRNA-directed inhibition of HIV-1 infection. Nat Med (2002) 6.36
Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med (2003) 5.71
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol (2005) 5.37
Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature (2005) 4.71
T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell (2008) 4.32
Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol (2008) 4.29
Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc Natl Acad Sci U S A (2007) 3.94
Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release (2006) 3.85
Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science (2008) 3.51
Diffusion of macromolecules and virus-like particles in human cervical mucus. Biophys J (2001) 3.18
Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J (2002) 3.13
Current status of polymeric gene delivery systems. Adv Drug Deliv Rev (2006) 3.04
Polyamines in cell growth and cell death: molecular mechanisms and therapeutic applications. Cell Mol Life Sci (2001) 2.99
An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature (2005) 2.87
Microbicides: a new approach to preventing HIV and other sexually transmitted infections. Nat Rev Drug Discov (2002) 2.78
Polymer microspheres for controlled drug release. Int J Pharm (2004) 2.34
Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc Natl Acad Sci U S A (2003) 2.34
Dynamics of endocytosis and exocytosis of poly(D,L-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells. Pharm Res (2003) 2.32
Whither or wither microbicides? Science (2008) 2.17
Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. Hum Gene Ther (2008) 2.06
Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv Drug Deliv Rev (2005) 1.89
Cationic lipids and polymers mediated vectors for delivery of siRNA. J Control Release (2007) 1.79
Biophysical and structural characterization of polyethylenimine-mediated siRNA delivery in vitro. Pharm Res (2006) 1.78
Polyamine-dependent gene expression. Cell Mol Life Sci (2003) 1.74
Improving protein therapeutics with sustained-release formulations. Nat Biotechnol (1998) 1.73
The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemics. Proc Natl Acad Sci U S A (2008) 1.64
Breaking up the correlation between efficacy and toxicity for nonviral gene delivery. Proc Natl Acad Sci U S A (2007) 1.58
Controlled release of antibodies for long-term topical passive immunoprotection of female mice against genital herpes. Nat Biotechnol (1996) 1.57
Characterization of cationic lipid-protamine-DNA (LPD) complexes for intravenous gene delivery. Gene Ther (1998) 1.36
Inhibition of cervical cancer cell growth in vitro and in vivo with lentiviral-vector delivered short hairpin RNA targeting human papillomavirus E6 and E7 oncogenes. Cancer Gene Ther (2006) 1.19
Implications of pharmacokinetic behavior of lipoplex for its inflammatory toxicity. Adv Drug Deliv Rev (2005) 1.10
Anti-tumor effects of anti-VEGF siRNA encapsulated with PLGA microspheres in mice. J Control Release (2007) 1.10
Sustained polymeric delivery of gene silencing antisense ODNs, siRNA, DNAzymes and ribozymes: in vitro and in vivo studies. J Drug Target (2004) 1.05
Gene expression and mucosal immune responses after vaginal DNA immunization in mice using a controlled delivery matrix. J Control Release (2003) 1.01
Naturally occurring polyamines: interaction with macromolecules. Curr Protein Pept Sci (2005) 1.00
Lipoplexes prepared from cationic liposomes and mammalian DNA induce CpG-independent, direct cytotoxic effects in cell cultures and in mice. J Gene Med (2006) 0.90
Efficient delivery of small interfering RNA for inhibition of IL-12p40 expression in vivo. J Inflamm (Lond) (2004) 0.90
Several serum proteins significantly decrease inflammatory response to lipid-based non-viral vectors. Mol Ther (2007) 0.87
SiRNA drug delivery by biodegradable polymeric nanoparticles. J Nanosci Nanotechnol (2006) 0.87
NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell (2011) 9.75
Caspases 3 and 7: key mediators of mitochondrial events of apoptosis. Science (2006) 6.55
A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol (2009) 5.26
Wnk4 controls blood pressure and potassium homeostasis via regulation of mass and activity of the distal convoluted tubule. Nat Genet (2006) 3.57
Th17 cells express interleukin-10 receptor and are controlled by Foxp3⁻ and Foxp3+ regulatory CD4+ T cells in an interleukin-10-dependent manner. Immunity (2011) 3.38
GBP5 promotes NLRP3 inflammasome assembly and immunity in mammals. Science (2012) 2.69
Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A (2012) 2.59
Tissue-engineered vascular grafts transform into mature blood vessels via an inflammation-mediated process of vascular remodeling. Proc Natl Acad Sci U S A (2010) 2.49
The lncRNA Malat1 is dispensable for mouse development but its transcription plays a cis-regulatory role in the adult. Cell Rep (2012) 2.45
IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine. Nature (2012) 2.36
Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc Natl Acad Sci U S A (2010) 2.33
Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma. Proc Natl Acad Sci U S A (2013) 1.95
Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology (2006) 1.92
Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proc Natl Acad Sci U S A (2012) 1.91
A cross-sectional survey on prevalence and risk factors for persistent postsurgical pain 1 year after total hip and knee replacement. Reg Anesth Pain Med (2012) 1.86
The uptake and intracellular fate of PLGA nanoparticles in epithelial cells. Biomaterials (2009) 1.82
Aging promotes neutrophil-induced mortality by augmenting IL-17 production during viral infection. Cell Host Microbe (2009) 1.78
PEGylated PLGA nanoparticles for the improved delivery of doxorubicin. Nanomedicine (2009) 1.70
Paradoxical role of the proto-oncogene Axl and Mer receptor tyrosine kinases in colon cancer. Proc Natl Acad Sci U S A (2013) 1.64
Controlled surface modification with poly(ethylene)glycol enhances diffusion of PLGA nanoparticles in human cervical mucus. Mol Pharm (2009) 1.59
Multiphoton microscopy guides neurotrophin modification with poly(ethylene glycol) to enhance interstitial diffusion. Nat Mater (2004) 1.59
Tissue-engineered vascular grafts form neovessels that arise from regeneration of the adjacent blood vessel. FASEB J (2011) 1.52
Pharmacokinetics of the carmustine implant. Clin Pharmacokinet (2002) 1.52
The influence of microchannels on neurite growth and architecture. Biomaterials (2005) 1.47
Surface-mediated gene transfer from nanocomposites of controlled texture. Nat Mater (2004) 1.45
Viral infection of the placenta leads to fetal inflammation and sensitization to bacterial products predisposing to preterm labor. J Immunol (2010) 1.39
A proinflammatory role for interleukin-22 in the immune response to hepatitis B virus. Gastroenterology (2011) 1.38
Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors. Biomaterials (2011) 1.36
Therapeutic siRNA: principles, challenges, and strategies. Yale J Biol Med (2012) 1.35
Biodegradable poly(amine-co-ester) terpolymers for targeted gene delivery. Nat Mater (2011) 1.33
Absence of innate MyD88 signaling promotes inducible allograft acceptance. J Immunol (2006) 1.33
FAT10/diubiquitin-like protein-deficient mice exhibit minimal phenotypic differences. Mol Cell Biol (2006) 1.32
Human aortic smooth muscle cells promote arteriole formation by coengrafted endothelial cells. Tissue Eng Part A (2009) 1.28
New methods for direct delivery of chemotherapy for treating brain tumors. Yale J Biol Med (2006) 1.26
Dilation and degradation of the brain extracellular matrix enhances penetration of infused polymer nanoparticles. Brain Res (2007) 1.25
Enhanced siRNA delivery into cells by exploiting the synergy between targeting ligands and cell-penetrating peptides. Biomaterials (2011) 1.24
Controlled delivery of VEGF via modulation of alginate microparticle ionic crosslinking. J Control Release (2008) 1.23
In vivo distribution of surface-modified PLGA nanoparticles following intravaginal delivery. J Control Release (2011) 1.20
Cellular fate of a modular DNA delivery system mediated by silica nanoparticles. Biotechnol Prog (2005) 1.19
Antibodies against a tick protein, Salp15, protect mice from the Lyme disease agent. Cell Host Microbe (2009) 1.19
High loading efficiency and tunable release of plasmid DNA encapsulated in submicron particles fabricated from PLGA conjugated with poly-L-lysine. J Control Release (2008) 1.19
Diffusion of nerve growth factor in rat striatum as determined by multiphoton microscopy. Biophys J (2003) 1.17
Fibronectin terminated multilayer films: protein adsorption and cell attachment studies. Biomaterials (2006) 1.16
Inhibition of neutrophil function by two tick salivary proteins. Infect Immun (2009) 1.16
Biomaterials with hierarchically defined micro- and nanoscale structure. Biomaterials (2004) 1.15
Nanoparticles deliver triplex-forming PNAs for site-specific genomic recombination in CD34+ human hematopoietic progenitors. Mol Ther (2010) 1.13
Recruitment of macrophages and polymorphonuclear leukocytes in Lyme carditis. Infect Immun (2006) 1.12
Poly(omega-pentadecalactone-co-butylene-co-succinate) nanoparticles as biodegradable carriers for camptothecin delivery. Biomaterials (2009) 1.12
Centrifugal seeding increases seeding efficiency and cellular distribution of bone marrow stromal cells in porous biodegradable scaffolds. Tissue Eng (2007) 1.12
Immunity against Ixodes scapularis salivary proteins expressed within 24 hours of attachment thwarts tick feeding and impairs Borrelia transmission. PLoS One (2007) 1.11
Engineering of multifunctional gels integrating highly efficient growth factor delivery with endothelial cell transplantation. FASEB J (2008) 1.11
Predictors for moderate to severe acute postoperative pain after total hip and knee replacement. Int Orthop (2012) 1.11
Polymeric nanoparticles for drug delivery to the central nervous system. Adv Drug Deliv Rev (2011) 1.09
Improving the expansion and neuronal differentiation of mesenchymal stem cells through culture surface modification. Biomaterials (2003) 1.09
A self-assembled, modular DNA delivery system mediated by silica nanoparticles. J Control Release (2004) 1.07
Convection-enhanced delivery of camptothecin-loaded polymer nanoparticles for treatment of intracranial tumors. Drug Deliv Transl Res (2011) 1.07
Development of a model system for preliminary evaluation of tissue-engineered vascular conduits. J Pediatr Surg (2006) 1.06
The immunoconjugate "icon" targets aberrantly expressed endothelial tissue factor causing regression of endometriosis. Am J Pathol (2009) 1.06
ErbB3 is required for ductal morphogenesis in the mouse mammary gland. Breast Cancer Res (2008) 1.06
Marginal zone B-cell depletion impairs murine host defense against Borrelia burgdorferi infection. Infect Immun (2007) 1.05
Enhancement of surface ligand display on PLGA nanoparticles with amphiphilic ligand conjugates. J Control Release (2011) 1.03
Nanotechnology for delivery of drugs to the brain for epilepsy. Neurotherapeutics (2009) 1.03
Novel delivery strategies for glioblastoma. Cancer J (2012) 1.01
Gene expression and mucosal immune responses after vaginal DNA immunization in mice using a controlled delivery matrix. J Control Release (2003) 1.01
Dual delivery of VEGF and MCP-1 to support endothelial cell transplantation for therapeutic vascularization. Biomaterials (2010) 0.99
Partial correction of cystic fibrosis defects with PLGA nanoparticles encapsulating curcumin. Mol Pharm (2010) 0.99
Canonical and non-canonical barriers facing antimiR cancer therapeutics. Curr Med Chem (2013) 0.98
Nanosystems for simultaneous imaging and drug delivery to T cells. AAPS J (2007) 0.98
Induced hepatic fibrosis in rats: hepatic steatosis, macromolecule content, perfusion parameters, and their correlations--preliminary MR imaging in rats. Radiology (2008) 0.98
Topographical control of human neutrophil motility on micropatterned materials with various surface chemistry. Biomaterials (2002) 0.98
In vitro evaluation of biodegradable microspheres with surface-bound ligands. J Control Release (2005) 0.97
Surface modified poly(β amino ester)-containing nanoparticles for plasmid DNA delivery. J Control Release (2012) 0.97
Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial. Hum Gene Ther (2015) 0.97
In vitro cytotoxicity and in vivo distribution after direct delivery of PEG-camptothecin conjugates to the rat brain. Bioconjug Chem (2004) 0.96
Polymer nanoparticle-mediated delivery of microRNA inhibition and alternative splicing. Mol Pharm (2012) 0.96
Bioengineering approaches to controlled protein delivery. Pediatr Res (2008) 0.95
Polymer nanoparticles encapsulating siRNA for treatment of HSV-2 genital infection. J Control Release (2012) 0.95
Improved cell adhesion and proliferation on synthetic phosphonic acid-containing hydrogels. Biomaterials (2005) 0.94
Sustained delivery of proangiogenic microRNA-132 by nanoparticle transfection improves endothelial cell transplantation. FASEB J (2013) 0.94
The caspase 1 inflammasome is not required for control of murine Lyme borreliosis. Infect Immun (2009) 0.93
Age-associated variability in susceptibility of Swiss Webster mice to MPV and other excluded murine pathogens. J Am Assoc Lab Anim Sci (2012) 0.93
Ligand-modified gene carriers increased uptake in target cells but reduced DNA release and transfection efficiency. Nanomedicine (2009) 0.92
ICOS mediates the development of insulin-dependent diabetes mellitus in nonobese diabetic mice. J Immunol (2008) 0.92
IL-22 promotes fibroblast-mediated wound repair in the skin. J Invest Dermatol (2012) 0.91
Drug delivery: Stealth particles give mucus the slip. Nat Mater (2009) 0.91
Polymer nanoparticles containing tumor lysates as antigen delivery vehicles for dendritic cell-based antitumor immunotherapy. Nanomedicine (2010) 0.90
Design opportunities for actively targeted nanoparticle vaccines. Nanomedicine (Lond) (2008) 0.89
Bortezomib inhibits hepatitis B virus replication in transgenic mice. Antimicrob Agents Chemother (2009) 0.89
Pericytes modulate endothelial sprouting. Cardiovasc Res (2013) 0.89
Mathematical modeling of molecular diffusion through mucus. Adv Drug Deliv Rev (2008) 0.89
Fetal nucleated red blood cells in a rat model of intrauterine growth restriction induced by hypoxia and nitric oxide synthase inhibition. Am J Obstet Gynecol (2007) 0.88
The kinase VRK1 is required for normal meiotic progression in mammalian oogenesis. Mech Dev (2011) 0.88